| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Investigations |
University of Siena, Siena, Italy
Percutaneous ethanol injection (PEI) has traditionally been used in the management of small hepatocellular carcinomas, metastatic liver lesions, primary or secondary parathyroid adenomas, and, sporadically, other benign endocrine neoplasms such as aldosterone-producing adrenocortical adenomas (1–5).
The use of PEI in the management of autonomous functioning thyroid nodules (AFTNs) was introduced into clinical practice by Livraghi et al. (6) in 1990. Since then, several other series (7–14) have shown that PEI represents an effective alternative to surgery and radioiodine for the treatment of AFTNs. Normal thyroid function is restored in nearly 100% of patients with subclinical hyperthyroidism and in 52%–80% of those with overt hyperthyroidism. In addition, significant nodule shrinkage (21%–88% of the pretreatment volume) is obtained in most cases, and follow-up data indicate a low rate of recurrence and of permanent hypothyroidism. Side effects are frequent but are generally mild, consisting of local pain, sometimes radiating to the upper neck, but on certain occasions the pain is so severe that the patient refuses further treatment. In sporadic cases, major complications, such as transient vocal cord palsy and venous thrombosis, have been reported.
The most important factor affecting the rate of success seems to be the skillfulness of the operator, together with an accurate selection of cases. The therapeutic effect is better in small nodules (3 cm or less), but large nodules have occasionally been treated with success (15–18). The article by Zingrillo et al. (19) in this issue of The Journal of Nuclear Medicine selectively studied the indication of PEI in large toxic thyroid nodules. The authors randomly assigned 22 patients with toxic thyroid adenomas larger than 4 cm to receive radioiodine therapy alone or radioiodine therapy preceded by 2–4 sessions of PEI. The results of the study showed that, after 12 mo of follow-up, all patients achieved adequate control of hyperthyroidism, and those treated with PEI plus radioiodine had a significantly higher reduction of nodule volume and of local symptoms compared with patients treated with radioiodine alone.
The merit of this new approach is evident: It allows one to avoid a surgical procedure in patients with locally symptomatic large thyroid nodules whose response to radioiodine alone is poor, at least in terms of nodule shrinkage. Another obvious advantage is that side effects from PEI are limited to a few sessions, since the intent of PEI in this context is not to cure the nodule but just to offer a shrunken nodule to the subsequent action of radioiodine. Furthermore, pretreatment with PEI shrinks the nodules before radioiodine therapy, thus allowing the administration of lower doses of 131I. The caveat is that, despite normalization of serum thyroid-stimulating hormone concentrations, the posttreatment scan showed evidence of autonomous nodular tissue suppressing the function of the extranodular tissue in nearly 50% of patients (as observed also in patients treated with radioiodine alone). This finding should alert one to the possibility of later relapse of hyperthyroidism and calls for further confirmatory studies with longer follow-up.
PEI has also been proposed for the treatment of cold benign thyroid nodules (20,21) and thyroid cysts (22,23). A randomized study from Bennedbaek et al. (24) showed that a single injection of ethanol in a mean dose equal to 21% of the nodule volume produced a mean reduction in nodule volume of 47%, compared with 9% in the control group treated with L-thyroxine–suppressive therapy. Relief of compressive symptoms was experienced by 56% of the PEI-treated patients versus 32% in the group treated with L-thyroxine. In another study from the same authors (25), increasing the number of PEI sessions did not result in additional benefit.
Cold thyroid nodules are treated in many centers by surgery, if indicated, or by long-term administration of thyroid-stimulating hormone–suppressive therapy. The benefits of the latter treatment are controversial, at least in the case of single thyroid nodules without goiter. The possibility of alternative therapies such as PEI is attractive but must be balanced against 2 main concerns: the eventuality that cold nodules may harbor an incidental cancer and the frequency of side effects. Although thyroid malignancy may be ruled out by fine-needle aspiration cytology before PEI, Monzani et al. (26) reported the presence of papillary cancer in 1 of 12 PEI-treated nodules that were treated by surgery because of PEI failure. Major side effects consisting of permanent ipsilateral facial dysesthesia, an increased flow of tears, and paranodular fibrosis resulting from subsequent surgery have been reported (25). Of course, side effects depend on the selection of patients, the number of injections, and the skillfulness of the operator.
More convincing is the use of PEI in patients with thyroid cysts. In this case, the presence of a fibrous capsule surrounding the cysts and the absence of sensitive nerves prevents accidental leakage of ethanol into the surrounding normal thyroid tissue and avoids pain. The technique is simple (a single session is usually effective), shrinkage of the nodule is impressive, and recurrences are limited and can be treated with a second injection. The general impression is that PEI treatment may be the first-line procedure for the definitive treatment of thyroid cysts.
In conclusion, the article by Zingrillo et al. (19) proposes some kind of "adjuvant" PEI treatment to assist radioiodine therapy. If confirmed in subsequent studies, this approach may become a useful tool for the management of large toxic thyroid nodules. In contrast, the use of PEI as the single form of treatment of thyroid nodules remains indicated only in selected patients: those who have small, easily accessible hot nodules; those who refuse radioiodine therapy; and those who are at high risk of surgical morbidity. According to these restrictions, the final number of candidates for PEI treatment is limited and will probably be further reduced by the advent of new therapeutic strategies that carry limited surgical risks, such as video-assisted thyroid lobectomy (27), or are more comfortable for patients, such as interstitial laser photocoagulation, cryoablation, radiofrequency thermal ablation, and microwave destruction.
 |
FOOTNOTES |
|---|
For correspondence or reprints contact: Furio Pacini, MD, Department of Endocrinology, Viale Bracci, Siena 53100, Italy.
E-mail: pacini8{at}unisi.it
|
REFERENCES |
|---|
 TOP REFERENCES |
|---|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
